<DOC>
	<DOCNO>NCT01090817</DOCNO>
	<brief_summary>Despite advent new biologic therapy infliximab Crohn 's disease , form autoimmune inflammatory bowel disease , proportion patient refractory therapy require surgery . The hypothesis mesenchymal stromal cell therapy use third party human culture cell safe effective</brief_summary>
	<brief_title>An Australian Study Mesenchymal Stromal Cells Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Colonic small bowel Crohn 's disease base endoscopic appearance histology Refractory induction infliximab adalimumab ; lose response agent ; side effect preclude use Where loss response one agent , must try eligible Crohn 's disease activity score ( CDAI ) 250 . Creactive protein &gt; 10mg/L Surgery must offer subject ( appropriate ) decline Signed inform consent Active sepsis , perforate disease . Coexistent perianal fistulous disease permit , provide coexistent infection within previous 4 week Chronic stricturing disease isolation Coexistent CMV disease Prior history malignancy Pregnant unwilling practice contraceptive therapy breast feeding female Last biologic therapy must great 4 week prior , must stable corticosteroid dose 14 day prior , therapy 14 day therapy , must stable immunomodulator dose ( eg , azathioprine ) 14 day prior , therapy 14 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>mesenchymal stromal cell</keyword>
	<keyword>ileitis</keyword>
	<keyword>colitis</keyword>
</DOC>